These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 22855599)
1. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Gönen M; Sun Z; Figueroa ME; Patel JP; Abdel-Wahab O; Racevskis J; Ketterling RP; Fernandez H; Rowe JM; Tallman MS; Melnick A; Levine RL; Paietta E Blood; 2012 Sep; 120(11):2297-306. PubMed ID: 22855599 [TBL] [Abstract][Full Text] [Related]
2. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Luskin MR; Lee JW; Fernandez HF; Abdel-Wahab O; Bennett JM; Ketterling RP; Lazarus HM; Levine RL; Litzow MR; Paietta EM; Patel JP; Racevskis J; Rowe JM; Tallman MS; Sun Z; Luger SM Blood; 2016 Mar; 127(12):1551-8. PubMed ID: 26755712 [TBL] [Abstract][Full Text] [Related]
3. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations. Zheng WS; Hu YL; Guan LX; Peng B; Wang SY Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943 [TBL] [Abstract][Full Text] [Related]
4. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia. Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287 [TBL] [Abstract][Full Text] [Related]
5. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients. Aref S; Azmy E; El Ghannam D; Haroun M; Ibrahim L; Sabry M Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762 [TBL] [Abstract][Full Text] [Related]
6. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia. Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000 [TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. Patel JP; Gönen M; Figueroa ME; Fernandez H; Sun Z; Racevskis J; Van Vlierberghe P; Dolgalev I; Thomas S; Aminova O; Huberman K; Cheng J; Viale A; Socci ND; Heguy A; Cherry A; Vance G; Higgins RR; Ketterling RP; Gallagher RE; Litzow M; van den Brink MR; Lazarus HM; Rowe JM; Luger S; Ferrando A; Paietta E; Tallman MS; Melnick A; Abdel-Wahab O; Levine RL N Engl J Med; 2012 Mar; 366(12):1079-89. PubMed ID: 22417203 [TBL] [Abstract][Full Text] [Related]
8. CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. Fujiwara SI; Muroi K; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Ozawa K Hematology; 2017 Jul; 22(6):347-353. PubMed ID: 28097942 [TBL] [Abstract][Full Text] [Related]
9. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610 [TBL] [Abstract][Full Text] [Related]
10. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P; Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335 [TBL] [Abstract][Full Text] [Related]
11. CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Allan JN; Roboz GJ; Askin G; Ritchie E; Scandura J; Christos P; Hassane DC; Guzman ML Leuk Lymphoma; 2018 Apr; 59(4):821-828. PubMed ID: 28718760 [TBL] [Abstract][Full Text] [Related]
12. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943 [TBL] [Abstract][Full Text] [Related]
13. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. LaRochelle O; Bertoli S; Vergez F; Sarry JE; Mansat-De Mas V; Dobbelstein S; Dastugue N; Strzelecki AC; Cavelier C; Creancier L; Pillon A; Kruczynski A; Demur C; Sarry A; Huguet F; Huynh A; Récher C; Delabesse E Oncotarget; 2011 Nov; 2(11):850-61. PubMed ID: 22081665 [TBL] [Abstract][Full Text] [Related]
14. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Zwaan CM; Meshinchi S; Radich JP; Veerman AJ; Huismans DR; Munske L; Podleschny M; Hählen K; Pieters R; Zimmermann M; Reinhardt D; Harbott J; Creutzig U; Kaspers GJ; Griesinger F Blood; 2003 Oct; 102(7):2387-94. PubMed ID: 12816873 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis. Nakase K; Kita K; Kyo T; Ueda T; Tanaka I; Katayama N PLoS One; 2015; 10(9):e0128998. PubMed ID: 26375984 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation. Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446 [TBL] [Abstract][Full Text] [Related]
17. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Staffas A; Kanduri M; Hovland R; Rosenquist R; Ommen HB; Abrahamsson J; Forestier E; Jahnukainen K; Jónsson ÓG; Zeller B; Palle J; Lönnerholm G; Hasle H; Palmqvist L; Ehrencrona H; Blood; 2011 Nov; 118(22):5905-13. PubMed ID: 21967978 [TBL] [Abstract][Full Text] [Related]
18. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330 [TBL] [Abstract][Full Text] [Related]
19. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China. Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635 [TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]